| Autor: |
Wang DM; Department of Pharmacology and Regenerative Medicine, College of Medicine, University of Illinois, Chicago, IL 60612., Soni D; Department of Pharmacology and Regenerative Medicine, College of Medicine, University of Illinois, Chicago, IL 60612., Regmi SC; Department of Pharmacology and Regenerative Medicine, College of Medicine, University of Illinois, Chicago, IL 60612., Vogel SM; Department of Pharmacology and Regenerative Medicine, College of Medicine, University of Illinois, Chicago, IL 60612., Tiruppathi C; Department of Pharmacology and Regenerative Medicine, College of Medicine, University of Illinois, Chicago, IL 60612. |
| Abstrakt: |
TGF-β-activated kinase 1 (TAK1) plays crucial roles in innate and adaptive immune responses and is required for embryonic vascular development. However, TAK1's role in regulating vascular barrier integrity is not well defined. Here we show that endothelial TAK1 kinase function is required to maintain and repair the injured lung endothelial barrier. We observed that inhibition of TAK1 with 5Z-7-oxozeaenol markedly reduced expression of β-catenin (β-cat) and VE-cadherin at endothelial adherens junctions and augmented protease-activated receptor-1 (PAR-1)- or toll-like receptor-4 (TLR-4)-induced increases in lung vascular permeability. In inducible endothelial cell (EC)-restricted TAK1 knockout ( TAK1 i∆EC ) mice, we observed that the lung endothelial barrier was compromised and in addition, TAK1 i∆EC mice exhibited heightened sensitivity to septic shock. Consistent with these findings, we observed dramatically reduced β-cat expression in lung ECs of TAK1 i∆EC mice. Further, either inhibition or knockdown of TAK1 blocked PAR-1- or TLR-4-induced inactivation of glycogen synthase kinase 3β (GSK3β), which in turn increased phosphorylation, ubiquitylation, and degradation of β-cat in ECs to destabilize the endothelial barrier. Importantly, we showed that TAK1 inactivates GSK3β through AKT activation in ECs. Thus our findings in this study point to the potential of targeting the TAK1-AKT-GSK3β axis as a therapeutic approach to treat uncontrolled lung vascular leak during sepsis. |
